Northera
| Chemical Name | droxidopa |
| Dosage Form | Capsules (oral; 100 mg, 200 mg, 300 mg) |
| Drug Class | Unknown mechanism of action |
| System | Cardiovascular |
| Company | Lundbeck |
| Approval Year | 2014 |
Indication
- For the treatment of orthostatic dizziness and light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropath.